Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Fraiser Kansteiner, and we will feature it here at the end of each week.
Frazier to retire as Merck CEO after 10-year run, handing the baton to CFO Davis
Sponsored By Syneos Health
- 1.1 Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders
- 1.2 Lilly cancer R&D chief Bilenker quits, handing reins to deputy
- 1.3 Shih, fresh from selling Disarm to Lilly, takes up CEO post at CAR-NK specialist Catamaran
Merck & Co.
Ken Frazier will step down as CEO.
Frazier will retire June 30, passing the chief executive mantle to current CFO Robert Davis. Frazier has served at Merck since 1992 and acted as CEO since 2011. He’ll continue to serve as executive chairman for a transition period that’s yet to be determined. Frazier is credited with leading the litigation around top-selling painkiller Vioxx, now withdrawn for safety reasons. He’s also won praise for turning out enviable growth at Merck with the launch of innovative medicines—most notably, the company’s best-selling drug Keytruda. Fierce Pharma
Lilly cancer R&D chief Bilenker quits, handing reins to deputy
Josh Bilenker, M.D., is leaving his cancer R&D chief post.
Bilenker, Lilly’s cancer R&D chief, is taking his leave two years after the company shelled out $8 billion for his startup, Loxo Oncology, and one year after combining Lilly Research Laboratories’ oncology team with Loxo’s. Bilenker, plus two other Loxo executives, were in charge of that combined effort. Meanwhile, Loxo’s chief operating officer, Jacob Van Naarden, is taking over the CEO role at the research unit, Loxo Oncology at Lilly. Bilenker will move into a consulting role with Lilly. It’s not yet clear what his next destination is, with the company saying he left to “focus on other interests and endeavors.” Fierce Biotech
Shih, fresh from selling Disarm to Lilly, takes up CEO post at CAR-NK specialist Catamaran
Alvin Shih, M.D., picks up the CEO torch.
Shih joins Catamaran after leading Disarm Therapeutics through its takeover by Eli Lilly. Last year, Shih nabbed a buyout bid from Lilly for Disarm, where he served as chief executive of the neurological disease biotech for about 18 months. Prior to that, Shih was CEO of Enzyvant Therapeutics, head of R&D at Retrophin and chief operating officer at Pfizer’s rare disease unit. Catamaran is keeping its pipeline close to the vest. It’s spoken about the potential benefits of its platform, dubbed Tailwind, and the engineered, off-the-shelf cell therapies it generates—and with two programs at the lead optimization stage, further details on Catamaran’s initial target and indications could emerge under Shih. Fierce Biotech
> Looking to expand its U.S. focus, Paris-based medtech Tissium has named Hunt Henrie as chief business officer and Seth Schulman as vice president of global regulatory affairs. Henrie most recently served as managing director and global head of medtech at Locust Walk. Schulman, meanwhile, joins from Penumbra, where he was vice president, regulatory affairs. Release
> CRISPR Therapeutics has tapped Philippe Drouet as chief commercial officer. Most recently, Drouet was senior vice president, global oncology marketing and market access at Merck & Co., where he launched and commercialized the company’s megablockbuster cancer med Keytruda. He also served as president of Hospira’s U.S. division before the company was bought out by Pfizer in 2015. Release
> Cambridge, Massachusetts-based Glympse Bio is bringing on Jessica Atkinson as senior vice president of business development. Atkinson joins with more than 14 years of experience in business development and commercialization across diagnostics and pharma. Most recently, Atkinson served as VP of biopharma business development at Foundation Medicine. Release
> Southlake, Texas’ OncoNano Medicine appointed Martin Driscoll to the position of CEO. Driscoll also signs on as a member of the company’s board of directors. Driscoll is replacing co-founder and CEO Ravi Srinivasan, Ph.D., who’s stepped down to pursue other interests. Most recently, Driscoll was president and CEO of Spring Bank Pharmaceuticals. Release (PDF)
> South San Francisco-based Unity Biotechnology named Przemyslaw (Mike) Sapieha, Ph.D., as chief scientific adviser. Sapieha will be based at Unity’s headquarters and joins the team effective immediately. Meanwhile, the company also promoted Jason Damiano, Ph.D., to VP of translational biology, while Nathan Guz, Ph.D., has moved up to the position of vice president of operations. Release
> Florida-based biotech Marizyme has tapped Roger Schaller as executive vice president of commercial operations, while Amy Chandler has been promoted to executive vice president for regulatory affairs and quality management systems. Schaller previously served as VP of business development at Silicon Valley company Promex Industries. Release
> Enanta Pharmaceuticals tapped Brendan Luu to join the company’s senior management team as SVP, business development. Luu joins off a 17-year stint at Merck & Co., where he was most recently vice president and global head of oncology business development. Release
> London-based contract research organization Quanticate named Lee Patterson as chief operation officer. Patterson will work across Quanticate’s global office network, spanning the U.K., North America, India, South Africa and Poland. Before joining the Quanticate team, Patterson held leadership posts at pharmas and CROs like Covance, Pathfinder Protek, Sanofi and Biomen Diagnostics. Release
> Moma Therapeutics has appointed Asit Parikh, M.D., Ph.D., as president and CEO, effective April 5. Parikh will replace interim founding CEO Reid Huber, Ph.D., a partner at Third Rock Ventures, who will remain on the company’s board of directors. Most recently, Parikh was senior vice president and head of Takeda’s gastroenterology unit—a position he held since 2012. Release
> Trevi Therapeutics tapped William Forbes as chief development officer. Forbes will be on deck to lead clinical development of the company’s drug Haduvio, which is currently in late-stage trials in its two lead indications. Before joining the Trevi team, Forbes served as founder, president and CEO of Vivelix Pharmaceuticals. Release
> Boston-based Cerevance appointed Carrie Ann Cook as chief business officer, effective Feb. 1. Before Cerevance, Cook was senior vice president and global head of business development at CANbridge Pharmaceuticals. Prior to that, she served as senior director, center for external innovation, rare disease, at Takeda Pharmaceuticals. Release
> OncoSec has signed on Brian Leuthner as chief operation officer, while Joe Smith joins on as vice president of business development. For a decade, Leuthner served as president, CEO and co-founder of Edge Therapeutics, and he led the merger of Edge with immuno-oncology firm PDS Biotechnology in 2019. Smith, meanwhile, was most recently an independent transaction adviser and acting head of business development to a number of biotechnology and specialty pharmaceutical companies. Release
> Biotech and medical device firm Windtree Therapeutics has named Joseph Soffer, M.D., as executive director of clinical development, effective immediately. A board-certified physician in cardiology and internal medicine, Soffer joins with more than 30 years combined experience in industry, clinical practice and academia. Most recently, he was senior medical director of clinical development at GlaxoSmithKline. Release